The Middle East and Africa Viral Inactivation Market was worth USD 22.86 million in 2018 and estimated to be growing at a CAGR of 12.7%, to reach USD 41.65 million by 2023. Viral Inactivation is the method by which virus cells are killed or made inactive. It is mainly done to prevent contamination of products by viruses and hence increase the safety. The viruses present in the final product are thus inactive. These methods are used a lot in food and blood plasma industries to protect the products from viruses.
Some of the methods which are used in virus inactivation are UV irradiation, pasteurization, lowering of pH, dry heating and solvent/detergent usage among others. Viral Inactivation by solvents and detergents is the most used method in the blood plasma industry. It is useful only if viruses are encapsulated in lipid molecules. The detergents/solvents disturb the lipid layers and destroy the viruses as they cannot live without lipid molecules. pH lowering is effective only if the molecules in the final product are more resistant than viruses. Similarly, Pasteurization is useful only if viruses to be killed are less resistant to heat than products to be saved. UV radiations eliminate the viruses by nucleic acid dimerization, thereby affecting their life cycle and reproduction processes.
The driving forces of Middle East and Africa Viral Inactivation market are increasing incidence of chronic diseases, growing support of government in biotechnology and pharmaceuticals industries, increasing attention of research and development sectors in life sciences, rising assistance of government to biotechnology and pharmaceuticals sectors and launch of new drugs among others. However the market is restrained by factors like presence of strong consolidation and less number of skilled workers.
The Middle East and Africa Viral Inactivation market is segmented on the basis of method, product, application and end-user. Based on method, the market is segmented into solvent/detergent method, pasteurization, UV radiation, microwave heating and high-energy light. The largest market share is held by solvent/detergent method since it requires less investment, easy to use and it achieves high degree of inactivation of viruses. Based on product the market is divided into services, kits and reagents, accessories and viral inactivation systems. With respect to application, the market is fragmented into vaccines and therapeutics, stem cell products, cell culture, gene therapy and blood & blood products. Vaccines and therapeutics has the largest share in this segment. Based on end-users, the market is segmented into academic institutions, research organisations, pharmaceutical companies and others.
The market is segmented based on geography broadly into Middle East and Africa. The market in this region is still in its nascent stages. Factors such as rising incidence of chronic diseases, increasing support of government organisations for pharmaceutical and biotechnology industries and introduction of new drugs into the market is expected to drive the growth in this region.
Some of the major players in the market include Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and WuXi Pharma Tech Inc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Solvent/Detergent Method
5.1.2 Pasteurization
5.1.3 UV Radiation
5.1.4 Microwave Heating
5.1.5 High-Energy Light
5.1.6 Y-o-Y Growth Analysis, By Method
5.1.7 Market Attractiveness Analysis, By Method
5.1.8 Market Share Analysis, By Method
5.2 Product
5.2.1 Kits and Reagents
5.2.2 Services
5.2.3 Accesories
5.2.4 Viral Inactivation Systems
5.2.5 Y-o-Y Growth Analysis, By Product
5.2.6 Market Attractiveness Analysis, By Product
5.2.7 Market Share Analysis, By Product
5.3 Application
5.3.1 Vaccines and Therapeutics
5.3.2 Stem Cell Products
5.3.3 Cell Culture
5.3.4 Gene Therapy
5.3.5 Blood & Blood Products
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.1 Pharmaceutical and Biotechnology Companies
5.4.2 Contract Research Organizations
5.4.3 Academic Research Institutes
5.4.4 Other End Users
5.4.5 Y-o-Y Growth Analysis, By End User
5.4.6 Market Attractiveness Analysis, By End User
5.4.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Method
6.1.3.2 By Product
6.1.3.3 By Application
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Method
6.1.4.2 By Product
6.1.4.3 By Application
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Method
6.1.5.2 By Product
6.1.5.3 By Application
6.1.5.4 By End User
6.2 Middle-East
6.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Clean Cells
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Charles River Laboratories International Inc.
8.3 Danaher Corporation
8.4 Merck KGaA
8.5 Parker Hannifin
8.6 Red Source Technologies
8.7 Sartorius AG
8.8 SGS S.A
8.9 Texcell Inc
8.10 Viral Inactivated Plasma Systems SA
8.11 WuXi Pharma Tech Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
